These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1478342)

  • 21. Strategies for the validation of viral inactivation in biologic products.
    Aronson DL
    Prog Clin Biol Res; 1990; 324():137-49. PubMed ID: 2408050
    [No Abstract]   [Full Text] [Related]  

  • 22. Removal of endogenous retrovirus-like particles from CHO-cell derived products using Q sepharose fast flow chromatography.
    Strauss DM; Lute S; Brorson K; Blank GS; Chen Q; Yang B
    Biotechnol Prog; 2009; 25(4):1194-7. PubMed ID: 19452543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Future development of harmonized guidelines.
    Hayakawa T
    Dev Biol Stand; 1996; 88():331-2. PubMed ID: 9119158
    [No Abstract]   [Full Text] [Related]  

  • 24. Chromatographic removal of viruses from plasma derivatives.
    Burnouf T
    Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Animal virus contaminants of biotechnology products.
    Onions D
    Dev Biol (Basel); 2004; 118():155-63. PubMed ID: 15645686
    [No Abstract]   [Full Text] [Related]  

  • 26. Viral safety evaluation of plasma-derived therapeutic products.
    Farshid M
    Dev Biol (Basel); 2004; 118():11-5. PubMed ID: 15645668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Licensing of protein products from the milk of transgenic animals. Validation for pathogen removal--a strategy.
    Wright G; Colman A; Cottom D; Williams M
    Dev Biol Stand; 1996; 88():269-76. PubMed ID: 9119150
    [No Abstract]   [Full Text] [Related]  

  • 28. Considerations in performing virus spiking experiments and process validation studies.
    Darling AJ
    Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics.
    Adamson SR
    Dev Biol Stand; 1998; 93():89-96. PubMed ID: 9737383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():177-201. PubMed ID: 9737396
    [No Abstract]   [Full Text] [Related]  

  • 31. Industry perspective for biotech products.
    Möritz A
    Dev Biol (Basel); 2004; 118():37-44. PubMed ID: 15645671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viral contamination of fetal bovine serum used for tissue culture: risks and concerns.
    Erickson GA; Bolin SR; Landgraf JG
    Dev Biol Stand; 1991; 75():173-5. PubMed ID: 1665460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration.
    Maerz H; Hahn SO; Maassen A; Meisel H; Roggenbuck D; Sato T; Tanzmann H; Emmrich F; Marx U
    Nat Biotechnol; 1996 May; 14(5):651-2. PubMed ID: 9630961
    [No Abstract]   [Full Text] [Related]  

  • 34. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (requirements for biological substances No 50).
    Dev Biol Stand; 1998; 93():141-71. PubMed ID: 9737395
    [No Abstract]   [Full Text] [Related]  

  • 35. Validation of removal of human retroviruses.
    Marcus-Sekura CJ
    Dev Biol Stand; 1992; 76():215-23. PubMed ID: 1478339
    [No Abstract]   [Full Text] [Related]  

  • 36. Strategies for viral removal and inactivation.
    Burstyn DG; Hageman TC
    Dev Biol Stand; 1996; 88():73-9. PubMed ID: 9119165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
    Hilfenhaus J; Niedrig M; Nowak T
    Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The hole story. Fine-pore membranes remove viruses from biological drugs.
    Erickson D
    Sci Am; 1992 Sep; 267(3):163-4. PubMed ID: 1502518
    [No Abstract]   [Full Text] [Related]  

  • 39. Virological aspects of the quality control of human monoclonal antibodies.
    Minor P
    Dev Biol Stand; 1991; 75():233-6. PubMed ID: 1794626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (Requirements for biological susbstances no. 50).
    Grachev V; Magrath D; Griffiths E
    Biologicals; 1998 Sep; 26(3):175-93. PubMed ID: 10208720
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.